In addition, our study found significantly higher expression of PDCD1 (PD-1), CTLA4, PDCD1LG2 (PD-L2), TIGIT, and LAG3 (CD223) in populations from the high risking part, which are potential targets for immunity checking point blockade treatment in ccRCC patients. The gene discussed is TIGIT; the disease is nonpapillary renal cell carcinoma.